Category: CAR T-Cell therapy

Home / Established Year

CAR T-Cell therapy for Chronic Lymphocytic Leukemia

CAR T-Cell therapy for Chronic Lymphocytic Leukemia

Introduction Chronic lymphocytic leukemia (CLL) is a long-lasting condition where mature B lymphocytes, which have encountered antigens before, become cancerous. This leads to the buildup of malignant B cells in the blood, bone m..

Lisocabtagene maraleucel is approved by FDA for relapsed or refractory mantle cell lymphoma

Lisocabtagene maraleucel is approved by FDA for relapsed or refractory mantle cell lymphoma

May 2024: The Food and Drug Administration has granted approval to lisocabtagene maraleucel (Breyanzi, Juno Therapeutics, Inc.) for the treatment of adult patients with relapsed or refractory mantle cell lymphoma (MCL) who have un..

Risk of developing secondary tumors following CAR-T cell therapy is minimal - A Stanford Study

Risk of developing secondary tumors following CAR-T cell therapy is minimal – A Stanford Study

June 2024: The chances of getting secondary blood cancers after CAR-T cell therapy, a cell-based cancer treatment that got a lot of attention in 2017 for being effective against hard-to-treat blood cancers, are very low, according..

Seattle Children's Hospital to Start CAR T-Cell Clinical Trial for Pediatric Lupus Patients

Seattle Children’s Hospital to Start CAR T-Cell Clinical Trial for Pediatric Lupus Patients

June 2024: Seattle Children's Hospital will initiate the inaugural clinical trial in the United States this summer to evaluate the efficacy of an autologous CAR T-cell treatment against a prevalent kind of lupus in pediatric patie..

Efficacy of CAR T Cell Therapy in B-Cell lymphoma Richter Transformation
, , ,

Efficacy of CAR T Cell Therapy in B-Cell lymphoma Richter Transformation

What is the Richter transformation? Richter transformation is an infrequent but not rare occurrence when an aggressive B-cell lymphoma develops in people with chronic lymphocytic leukemia or small lymphocytic lymphoma. The progno..

Claudin18.2-targeted CAR-T cell therapy brings complete remission in advanced pancreatic cancer patient A case report

Claudin18.2-targeted CAR-T cell therapy brings complete remission in advanced pancreatic cancer patient : A case report

Pancreatic cancer Pancreatic cancer, also referred to as the "king of cancers," is a highly deadly malignant tumor, with a survival rate of fewer than 10% over a 5-year period. As a result of inadequate screening methods, the maj..

What is the treatment after BCMA CAR T failed in RR multiple myeloma cases
,

What is the treatment after BCMA CAR T failed in R/R multiple myeloma cases?

OriCAR-017 for RRMM A top biopharmaceutical company in the clinical stage, Oricell Therapeutics, shared the long-term follow-up results of OriCAR-017, a Phase I study that looked at how well GPRC5D-targeted CAR-T therapy worked i..

CARSgen presents latest data of Satri-cel therapy in ASCO 2024

CARSgen presents latest data of Satri-cel therapy in ASCO 2024

Results of SATRi-cel therapy CARsgen Therapeutics Holdings Limited (Stock Code: 2171.HK) has released the latest findings from the investigator-initiated trial CT041-CG4006 (NCT03874897) of satricabtagene autoleucel ("satri-cel",..

Can CAR T cell therapy shortcomings be avoided by NK Cell therapy

Can CAR T cell therapy shortcomings be avoided by NK Cell therapy?

NK Cell therapy vs CAR T-Cell therapy The FDA's approval of the first CAR T cell therapy in 2017 was widely celebrated as a significant advancement in cancer treatment. The method enabled a focused assault on cancer cells by util..

CAR T Cell therapy for refractory systemic lupus erythematosus in China
,

CAR T Cell therapy for refractory systemic lupus erythematosus in China

What is systemic lupus erythematosus? Systemic lupus erythematosus (SLE) is defined by an abnormal immune response, resulting in a highly varied clinical presentation that can potentially impact many systems and organs. Although ..

Newer
Start chat
We Are Online! Chat With Us!
Scan the code
Hello,

Welcome to CancerFax !

CancerFax is a pioneering platform dedicated to connecting individuals facing advanced-stage cancer with groundbreaking cell therapies like CAR T-Cell therapy, Gene therapy, TIL therapy, and clinical trials worldwide.

Let us know what we can do for you.

1) CAR T-Cell therapy
2) Gene therapy
3) Gamma-Delta T Cell therapy
4) TIL therapy
5) NK Cell therapy